CLARUS THERAPEUTICS -CW27(NASDAQ:CRXTW) stock News

CRXTW Latest News, Press Relases and Analysis

All

Press Releases

3 years ago - By: Clarus Therapeutics Holdings, Inc. - Mentions: CRXT

Clarus Therapeutics Holdings, Inc. Announces Plan for Near-Term Sale of JATENZO® Using Structured Process Through Chapter 11 of the U.S. Bankruptcy Code

3 years ago - By: Clarus Therapeutics Holdings, Inc. - Mentions: CRXT

Clarus Therapeutics Reports Second Quarter 2022 Financial and Operating Results and Announces Workforce Reduction

3 years ago - By: Clarus Therapeutics Holdings, Inc. - Mentions: CRXT

Clarus Therapeutics Announces Notice of Allowance for Additional Patent Claims Covering JATENZO® (testosterone undecanoate)

3 years ago - By: Clarus Therapeutics Holdings, Inc. - Mentions: CRXT

Clarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at ENDO 2022, the Endocrine Society’s Annual Meeting

3 years ago - By: Clarus Therapeutics Holdings, Inc. - Mentions: CRXT

Clarus Therapeutics Announces Issuance of Patent Covering JATENZO® (testosterone undecanoate)

3 years ago - By: Clarus Therapeutics Holdings, Inc. - Mentions: CRXT

Clarus Therapeutics Reports First Quarter 2022 Financial and Operating Results

3 years ago - By: Clarus Therapeutics Holdings, Inc. - Mentions: CRXT

Clarus Therapeutics to Report First Quarter 2022 Financial and Operating Results

3 years ago - By: Clarus Therapeutics Holdings, Inc. - Mentions: CRXT

Clarus Therapeutics Announces Notice of Allowance for Patent Claims Covering CLAR-121 (Testosterone + Anastrozole) for Treatment of Androgen-Mediated Autoimmune Inflammatory Mastitis

3 years ago - By: Clarus Therapeutics Holdings, Inc. - Mentions: CRXT

Clarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at the 2022 American Urological Association Annual Meeting

3 years ago - By: Clarus Therapeutics Holdings, Inc. - Mentions: CRXT

Clarus Therapeutics Announces Notice of Allowance for Patent Claims Covering JATENZO® (testosterone undecanoate)

3 years ago - By: Clarus Therapeutics Holdings, Inc. - Mentions: CRXT

Clarus Therapeutics Announces Closing of Upsized $30.0 Million Underwritten Public Offering

3 years ago - By: Clarus Therapeutics Holdings, Inc. - Mentions: CRXT

Clarus Therapeutics Announces Pricing of Upsized $30.0 Million Underwritten Public Offering

3 years ago - By: Clarus Therapeutics Holdings, Inc. - Mentions: CRXT

Clarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at the Androgen Society 4th Annual Meeting

3 years ago - By: Clarus Therapeutics Holdings, Inc. - Mentions: CRXT

Clarus Therapeutics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results

3 years ago - By: Clarus Therapeutics Holdings, Inc. - Mentions: CRXT

Clarus Therapeutics to Report Fourth Quarter and Full Year 2021 Financial and Operating Results

4 years ago - By: Clarus Therapeutics Holdings, Inc. - Mentions: CRXT

Clarus Announces Initiation of Phase 4 Clinical Trial of JATENZO® (testosterone undecanoate) for the Treatment of Hypogonadal Men with Chronic Kidney Disease

4 years ago - By: Clarus Therapeutics Holdings, Inc. - Mentions: CRXT

Clarus Therapeutics to Present at the Oppenheimer 32nd Annual Healthcare Conference

4 years ago - By: Clarus Therapeutics Holdings, Inc. - Mentions: CRXT

Clarus Announces Strategic Partnerships for JATENZO® (testosterone undecanoate) with Vault Health and AssistRx – Leaders in Providing Healthcare Services to Patients

4 years ago - By: Clarus Therapeutics Holdings, Inc. - Mentions: CRXT

Clarus Therapeutics Appoints Dr. Zhanna Jumadilova as Chief Clinical Development Officer

4 years ago - By: Clarus Therapeutics Holdings, Inc. - Mentions: CRXT

Clarus Therapeutics Announces Closing of Approximately $15 Million Private Placement

4 years ago - By: Clarus Therapeutics Holdings, Inc. - Mentions: CRXT

Clarus Therapeutics Announces $15 Million Private Placement

4 years ago - By: Clarus Therapeutics Holdings, Inc. - Mentions: CRXT

Clarus Therapeutics Announces Issuance of Two New Patents for JATENZO® (testosterone undecanoate)

4 years ago - By: Clarus Therapeutics Holdings, Inc. - Mentions: CRXT

Clarus Therapeutics Reports Third Quarter 2021 Financial and Operating Results

4 years ago - By: Clarus Therapeutics Holdings, Inc. - Mentions: CRXT

Clarus Therapeutics to Report Third Quarter 2021 Financial and Operating Results

4 years ago - By: Clarus Therapeutics Holdings, Inc. - Mentions: CRXT

Clarus Therapeutics Announces Two Notices of Allowance for Patent Claims Covering JATENZO® (testosterone undecanoate)

4 years ago - By: Clarus Therapeutics Holdings, Inc. - Mentions: CRXT

Clarus Therapeutics to Present New Real-World Experience Data for JATENZO® (testosterone undecanoate) at the 22nd Annual Fall Scientific Meeting of SMSNA

CLARUS THERAPEUTICS -CW27 (CRXTW) Stock News

CRXTW Latest News, Press Relases and Analysis